A drug used to treat coronavirus infections in cats could soon be used to treat Covid-19 in humans, after researchers demonstrated that the drug works as opposed to SARS-CoV2 coronavirus in laboratory experiments.
“In two months, our effects have shown that the drug is effective in inhibiting viral replication in SARS-CoV-2 cells,” said Joanne Lemieux, professor of biochemistry at the University of Alberta School of Medicine and Dentistry in Canada.
Research published in Nature Communications examines two very similar drugs called GC373 and GC376, both by inhibiting proteases, a type of enzyme widely discovered in various types of living beings, adding viruses and humans. Protects paints by decomposing proteins into smaller building blocks. Protease inhibitors prevent or slow down this process, restricting the replication of certain viruses. Several protease inhibitors are FDA approved for HIV remedy and researchers expect them to act the same way in SARS-CoV2 coronavirus.
Inflamed monkey cells and human lung cells with the SARS-CoV2 virus in lab boxes and tested protease inhibitors in them, and found that they were very effective at preventing replication of the virus.
“This drug is most likely for human paints, so we are encouraged to be an effective antiviral remedy for PATIENTS with COVID-19,” Lemieux said.
The coronavirus infection in cats that the drug has been shown to be effective in treatment is not the same as that of Covid-19 in humans. In cats, the infection is mild, but infrequently causes peritonitis, an abdominal infection that can be fatal. However, the researchers also tested precisely how the drugs join SARS-CoV2 protease and prevent the virus from replicaging, which assures them that the drug also has a smart chance of functioning in humans.
“In general, for a drug to be clinically tested, it will need to be confirmed in the laboratory and then tested on animal models. Because this drug has already been used to treat cats with coronavirus, and is effective with little or no toxicity, it has already passed those steps and this allows us to move on,” Lemieux said.
The drug worked in laboratory experiments at nanomolar concentrations, which meant that very little was needed to produce a significant effect on the virus. This is because if maximum concentrations of experimental drugs are needed in laboratory experiments, they are more likely to produce appearance effects in humans.
“Because of the falsified knowledge that we and others have gathered, we are conducting clinical trials for this drug as an antiviral Covid-19,” Lemieux said.
Researchers are working with Anvive Life Sciences, which produces the veterinary medicine drug, to produce the amount for a human clinical trial. The company is recently conducting more animal studies with the drug to determine its protection and the study team expects it to be tested. human until the end of this year.
Only another antiviral drug, remdesivir, has recently been approved for the Covid-19 remedy, after clinical trials have shown that it can boost recovery for some Patients with Covid-19; however, it is far from as expected. and if this protease inhibitor is promising in humans, it may only provide some other remedy option, although it will likely take some time to evaluate it.
Full policy and updates on the coronavirus
I am a postdoctoral researcher specializing in cancers years of training and new treatments for cancer. As a leukemia survivor of years of training, I am a
I am a postdoctoral student specializing in cancers of years of training and new targeted cancer remedies. As a leukemia survivor in the years of training, I am a strong advocate for studies on better and less poisonous cancer remedies and how to decrease the long-term side effects of existing drugs. I am an award-winning scientific communicator and have written for The Times, The Guardian and various cancer-focused media. I am also a 2017 TED Fellow, having given my TED talk on cancer survival and regularly giving public lectures on topics ranging from “Why haven’t we cured cancer yet?”A “Cannabis and cancer; hype or hope?” I am passionate about using social media to talk about science and percentages of images and stories from my own real-time lab paintings on my Twitter @vickyyyf, as well as comment on the advances in vital studies. You can find more information about me and how to touch me through my drvickyforster. com All my articles reflect my non-public perspectives and not those of my employer.